

## Environmental and Social Data Sheet<sup>1</sup>

### Overview

Project Name:	TECHEU VD DMS IMAGING (IEU LS)
Project Number:	2025-0272
Country:	France
Project Description:	The project supports the development, design and manufacturing of medical imaging systems. The financing includes new generation design, software development including AI modules, and modernization of manufacturing lines.

E&S Risk Categorisation:	Low risk
Invest EU sustainability proofing required	No
Project included in Carbon Footprint Exercise <sup>2</sup> :	No

### Environmental and Social Assessment

The project involves investments in Research and Development activities which are expected to have a low E&S risk.

#### Environmental Assessment

The project concerns investments in research and development activities carried out by the Company and its partners in existing facilities. The research and development activities of the project do not fall under either Annex I or Annex II of the EIA Directive 2011/92/EU amended by Directive 2014/52/EU.

<sup>1</sup> The information contained in the document reflects the requirement related to the environmental, social and climate information to be provided to Investment Committee as required by the Invest EU Regulation and it represents the equivalent of the information required in the template of the InvestEU sustainability proofing summary

<sup>2</sup> Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20 000 tonnes CO<sub>2</sub>e/year absolute (gross) or 20 000 tonnes CO<sub>2</sub>e/year relative (net) – both increases and savings.

**Climate Assessment*****Paris Alignment of projects:***

The project has been assessed for Paris alignment and is considered to be aligned with both low-carbon and resilience goals as per the policies set up in the Climate Bank Roadmap and/or associated guidance and other relevant documents (e.g. the Energy Lending Policy).

The Promoter is in scope but screened out of the PATH framework as it does not operate in a high-emitting sector and it is not considered as a highly-vulnerable counterpart.

**EIB Paris Alignment for Counterparties (PATH) Framework**

The Promoter is in scope but screened out of the PATH framework as it does not operate in a high-emitting sector and it is not considered as a highly-vulnerable counterpart.

**Other Environmental and Social Aspects**

The Company and its products are regulated to ensure quality and reliability of its medical products. Their quality management system is in compliance with the relevant quality management system regulations, and the company is seeking compliance of their devices and panels with EU Regulation 2017/746 of the European Parliament and of the Council of 5 April 2017 (MDR).

**Conclusions and Recommendations**

Through the R&D activities and investments, the Company is expected to sustain its current level of highly skilled personnel while contributing to European scientific innovation, supporting the vital research community.

The project concerns investments in research and development and its activities do not fall under either Annex I or Annex II of the EIA Directive 2011/92/EU amended by Directive 2014/52/EU.



Luxembourg, 04/12/2025

The Promoter has appropriate policies and operating procedures in place, which are in line with industry standards.

The project is carried out in compliance with applicable national and EU environmental and social legislation. Based on the environment, climate and social (ECS) information, the review of the ECS risks and impacts and the management systems in place, the project is deemed to have non-significant ECS risks impacts. No further sustainability proofing is required.